Therapeutic Efficacy of the Murine Precursor to PBD‐C06: a Novel CDC‐Mutant Anti‐pGlu3Aβ Mab

Pyroglutamate‐3Aβ (pGlu3Aβ) is a toxic N‐terminally truncated and modified form of Aβ that leads to faster aggregation and seeding of plaques, making it an important target in Alzheimer’s disease. Anti‐amyloid antibodies, e.g., bapineuzumab, are associated with Amyloid‐Related Imaging Abnormalities (ARIA) involving vasogenic edema and microhemorrhages in AD patients, especially in ApoE4 carriers. Previously, we demonstrated reductions in plaques and cognitive deficits using an anti‐pGlu3Ab mAb, 07/2a. Here, we tested a novel CDC‐mutant version (07/2a‐k, murine precursor to PBD‐C06) to avoid C1q activation to reduce vascular‐related inflammation associated with anti‐amyloid antibodies.